Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA.
Thromb Haemost. 2010 Jun;103(6):1233-8. doi: 10.1160/TH09-10-0732. Epub 2010 Mar 29.
Decreased levels of factor VIII (FVIII) limit the amount of thrombin generated at the site of injury, but not the rate that thrombin is neutralised by antithrombin (AT). We hypothesised that FVIII-deficient mice with heterozygous AT deficiency will demonstrate increased thrombin generation and therefore less in vivo bleeding compared to FVIII-deficient mice with normal AT levels. Therefore, we performed tail bleeding experiments in wild-type (WT), heterozygous AT deficient (AT(+/-)) mice, FVIII-deficient (FVIII(-/-)) mice, and FVIII-deficient mice with heterozygous AT deficiency (FVIII(-/-)/AT(+/-)). Amount of bleeding was assessed by measuring absorbance of haemoglobin released from lysed red blood cells collected after tail transection. In addition, we measured thrombin generation, activated partial thromboplastin time (aPTT), and AT activity in plasma from the different mice groups. Tail bleeding was significantly reduced in FVIII(-/-)/AT(+/-) mice compared to FVIII(-/-) mice. On the other hand, there was no difference in tail bleeding between AT(+/-) and wild-type mice. Thrombin generation was dependent on the mice genotype, and increased in the following order: FVIII(-/-) < FVIII(-/-)/AT(+/-) < WT < AT(+/-). The aPTT was not influenced by reduced AT activity (i.e. AT(+/-) genotype), but was significantly prolonged in FVIII(-/-) and FVIII(-/-)/AT(+/-) mice. Using FVIII-deficient mice as an in vivo murine model of reduced thrombin generation, we demonstrated that moderately reduced AT levels increase thrombin generation and decrease bleeding after traumatic tail vessel injury. In agreement with congenital thrombotic conditions, our data elucidate that bleeding phenotypes can be modulated by the balance between procoagulant and anticoagulant proteins.
VIII 因子(FVIII)水平降低会限制损伤部位凝血酶的生成量,但不会影响抗凝血酶(AT)对凝血酶的中和速度。我们假设,杂合 AT 缺乏的 FVIII 缺陷型小鼠会表现出更高的凝血酶生成,因此与 AT 水平正常的 FVIII 缺陷型小鼠相比,体内出血会更少。因此,我们在野生型(WT)、杂合 AT 缺乏(AT(+/-))小鼠、FVIII 缺陷(FVIII(-/-))小鼠和杂合 AT 缺乏的 FVIII 缺陷(FVIII(-/-)/AT(+/-))小鼠中进行了尾部出血实验。通过测量尾部横切后从裂解的红细胞中释放的血红蛋白的吸光度来评估出血量。此外,我们还测量了来自不同小鼠组的血浆中的凝血酶生成、活化部分凝血活酶时间(aPTT)和 AT 活性。与 FVIII(-/-)小鼠相比,FVIII(-/-)/AT(+/-)小鼠的尾部出血明显减少。另一方面,AT(+/-)和野生型小鼠之间的尾部出血没有差异。凝血酶生成依赖于小鼠的基因型,并且按照以下顺序增加:FVIII(-/-) < FVIII(-/-)/AT(+/-) < WT < AT(+/-)。aPTT 不受 AT 活性降低(即 AT(+/-)基因型)的影响,但在 FVIII(-/-)和 FVIII(-/-)/AT(+/-)小鼠中显著延长。使用 FVIII 缺陷型小鼠作为体内凝血酶生成减少的小鼠模型,我们证明了中度降低的 AT 水平会增加凝血酶生成,并减少创伤性尾部血管损伤后的出血。与先天性血栓形成条件一致,我们的数据阐明了出血表型可以通过促凝和抗凝蛋白之间的平衡来调节。